lunes, 4 de mayo de 2015

WHO Pharmaceuticals Newsletter No. 2, 2015




OMS, 4 de mayo de 2015

Contenidos

Regulatory Matters

Abiraterone acetate................................................................................... 4

Aceclofenac ............................................................................................. 4

Ambroxol and bromhexine expectorants ................................................. 4

Apixaban .................................................................................................. 5

Combined oral contraceptives and hormone replacement therapy .......... 5

Dabigatran and dronedarone or amiodarone ............................................ 6

Domperidone ............................................................................................ 6

Donepezil .................................................................................................. 7

Lamotrigine................................................................................................ 7

Memantine hydrochloride ......................................................................... 8

Metoclopramide ........................................................................................ 8

Montelukast sodium .................................................................................. 9

Mycophenolates ........................................................................................ 9

Telaprevir ............................................................................................... .10

Testosterone Products ............................................................................ .10

Tiotropium .............................................................................................. 11

Valproate-related medicines.................................................................... 11

Varenicline .............................................................................................. 12

Vemurafenib .............................................................................................13



Safety of medicines

Atypical Antipsychotics .........................................................................14

Nitric oxide (INOmax®) cylinders ........................................................14

Oral diclofenac .......................................................................................15

Ustekinumab ...........................................................................................15


Signal

Brentuximab and Hepatic disorders ........................................................ 17

Desloratadine and QT prolongation ........................................................ 23

Golimumab and Migraine ........................................................................27

Vemurafenib and Sepsis .......................................................................... 32


Feature

Recommendations from the Thirty-seventh Annual Meeting of National

Pharmacovigilance Centres ..................................................................... 38



disponible en http://bit.ly/1OTJEEU